Abbott: Psoriasis trials

The registry lists 16 Psoriasis studies with Abbott as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 1Phase 2 6Phase 3 8Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe PsoriasisCompletedNCT01126619Results posted
• Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic DrugsCompletedNCT01084668Results posted
• Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or FeetCompletedNCT00735787Phase 4Results posted
• Adalimumab in Adult Japanese Subjects With PsoriasisCompletedNCT00647400Phase 2/3Results posted
• Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic TreatmentCompletedNCT00574249Phase 3Results posted
• Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or PhototherapyCompletedNCT00566722Phase 3Results posted
• A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of PsoriasisCompletedNCT00513370Phase 3Results posted
• Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00195676Phase 3Results posted
• Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.WithdrawnNCT01260844Phase 1
• Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00646191Phase 2
• Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00645905Phase 2
• Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00645892Phase 2
• Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00645814Phase 2
• Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00338754Phase 2/3
• Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00237887Phase 3
• Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00235820Phase 3